Health Care & Life Sciences » Biotechnology | Molecular Partners Ltd.

Molecular Partners Ltd. | Cash Flow

Fiscal year is January-December. All values CHF Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
7,141.50
2,282.80
149.00
18,612.00
25,430.00
37,036
Depreciation, Depletion & Amortization
793.00
809.50
909.00
1,089.00
1,145.00
924
Other Funds
26,305.50
19,410.20
24,013.00
18,628.00
14,902.00
5,762
Funds from Operations
18,371.00
20,883.40
23,253.00
36,151.00
39,187.00
41,874
Changes in Working Capital
4,994.70
9,897.40
50,417.00
1,089.00
217.00
131
Net Operating Cash Flow
13,376.20
10,986.10
27,164.00
35,062.00
39,404.00
41,743
Capital Expenditures
1,473.70
546.10
1,387.00
1,097.00
500.00
Purchase/Sale of Investments
-
-
20,020.00
10,471.00
20,746.00
Net Investing Cash Flow
1,473.70
546.10
21,407.00
11,568.00
20,246.00
Net Financing Cash Flow
2,017.70
101,188.70
230.00
395.00
799.00
Net Change in Cash
17,061.80
92,256.10
6,987.00
45,635.00
18,419.00
Free Cash Flow
14,824.50
11,497.20
25,798.00
36,095.00
39,885.00
Change in Capital Stock
2,017.70
101,188.70
230.00
395.00
799.00
Exchange Rate Effect
194.20
2,599.60
1,000.00
600.00
60.00

About Molecular Partners

View Profile
Address
Wagistrasse 14
Zurich Zurich 8952
Switzerland
Employees -
Website http://www.molecularpartners.com
Updated 07/08/2019
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company was founded by Christian Zahnd, Patrick Amstutz, Patrik Forrer, Andreas Plückthun and Michael Tobias Stumpp on November 23, 2004 and is headquartered in Zurich, Switzerland.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.